A Fast CGP Panel with Guideline-Recommended Actionable Biomarkers
Our Guardant360 CDx test is our FDA-approved liquid biopsy that provides results in less than 7 days to inform treatment decisions.1 Guardant360 CDx has broad commercial and Medicare coverage for all advanced solid tumors.2
Liquid Comprehensive Genomic Profiling with an Expanded Panel of Biomarkers
The Guardant360 liquid biopsy test helps find additional treatment options with an expanded panel of biomarkers. Guardant360 has broad commercial and Medicare coverage for all advanced solid tumors.
The Only Tissue Comprehensive Genomic Profiling with AI-powered PD-L1 Detection
Our Guardant360 TissueNext tissue biopsy test finds actionable information when tissue testing is appropriate. The test leverages our AI-powered scoring algorithm to improve PD-L1 detection by >20% in NSCLC.3,4 Guardant360 TissueNext has broad commercial and Medicare coverage for advanced solid tumors.15
The only tissue comprehensive genomic profiling with AI-powered PD-L1 detection
Our Guardant360 TissueNext tissue biopsy test finds actionable information when tissue testing is appropriate. The test leverages our AI-powered scoring algorithm to improve PD-L1 detection by >20% in NSCLC.1,2 * Guardant360 TissueNext has broad commercial and Medicare coverage for advanced solid tumors.
*compared to manual pathologist interpretation in the most challenging cases in NSCLC
Guardant360 TissueNext Assay Specifications. Guardant Health Inc. Redwood City, CA.
Data on file. Guardant Health, Inc. Redwood City, CA.
Minimal Residual Disease Detection and Recurrence Monitoring
Guardant Reveal is a completely tissue-free test that detects circulating tumor DNA (ctDNA) for minimal residual disease (MRD) assessment in early-stage colorectal, breast, and lung cancers. In addition to detection of MRD, Guardant Reveal is also available to monitor recurrence in previously diagnosed patients.16
The Only Tissue-Free Biopsy to Measure Treatment Response
Our Guardant360 Response test is the first tissue-free biopsy that enables doctors to view molecular response, or changes in circulating tumor DNA (ctDNA) levels, to get an early indication of patient response to immunotherapy or targeted therapy for advanced stage solid tumors.17 Studies show the Guardant360 Response test can predict treatment response 8 weeks earlier than current standard-of-care imaging.4-13
On-demand medical experts to answer questions and guide clinical use of Guardant tests
Mobile Phlebotomy Services
An easy and convenience sample collection service that meets patients at their location
Guardant Access Program
Helps patients by minimizing surprise bills and checking eligibility for financial assistance
Digital Ordering with Guardant Portal and EMR Integrations
Simple paperless experience to speed up the ordering proces
Fastest average turnaround time from sample receipt to results based on stated average turnaround times from Integra Connect data.
In the event the test is not fully covered by insurance, patients may be eligible for financial assistance based on medical and financial need. To learn more, contact Guardant Health client services. For patients without insurance, the cash pay rate for Guardant360 CDx is $5,000 effective the first day of commercial launch September 28, 2020.
Guardant360(™) TissueNext Assay Specifications. Guardant Health Inc. Redwood City, CA.
Data on file. Guardant Health, Inc. Redwood City, CA.
Raja R, Kuziora M, Philip Z. Brohawn PZ, et al. Early Reduction in ctDNA Predicts Survival in Patients with Lung and Bladder Cancer Treated with Durvalumab. Clin Cancer Res; 2018: 24(24): 6212-6222. DOI: 10.1158/1078-0432.CCR-18-0386.
Aggarwal C,Thompson JC, Chien A, et al. Dynamic monitoring of circulating tumor DNA next-generation gene sequencing as a predictive biomarker of response and progression-free survival after pembrolizumab monotherapy in patients with advanced NSCLC.J Clin Oncol; 2019: 37:15 suppl, 3040-3040. DOI:10.1200/JCO.2019.37.15.
Kim ST, Cristescu R, Bass AJ, et al. Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. Nat Med; 2018: 24(9):1449-1458. DOI: 10.1038/s41591-018-0101-z.
Shaw AT, Martini JF, Besse B, et al. Early circulating tumor (ct)DNA dynamics and efficacy of lorlatinib in patients (pts) with advanced ALK-positive non-small cell lung cancer (NSCLC). J Clin Oncol; 2019: 37:15_suppl, 9019-9019. DOI: 10.1200/JCO.2019.37.15.
Pascual J, Cutts RJ, Kingston B, et al. Assessment of early ctDNA dynamics to predict efficacy of targeted therapies in metastatic breast cancer: Results from plasmaMATCH trial [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021;81(4 Suppl):Abstract nr PS5-02.DOI: 10.1158/1538-7445.SABCS20-PS5-02.
Mack PC, Redman MW, Moon J, et al. Residual circulating tumor DNA (ctDNA) after two months of therapy to predict progression-free and overall survival in patients treated on S1403 with afatinib +/- cetuximab.J Clin Oncol; 2020: 38:15_suppl, 9532-9532. DOI: 10.1200/JCO.2020.38.15.
Maron SB, Chatila WK, Millang BM, et al, Pembrolizumab with trastuzumab and chemotherapy (PTC) in HER2-positive metastatic esophagogastric cancer (mEG): Plasma and tumor-based biomarker analysis. J Clin Oncol; 2020: 38:15_suppl, 4559-4559. DOI: 10.1200/JCO.2020.38.15.
Modi S, Park H, Murthy RK, et al. Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study. J Clin Oncol; 2020: 38(17):1887-1896. DOI: 10.1200/JCO.19.02318.
Zhang Q, Luo J, Wu S, et al. Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade. Cancer Discov; 2020: 10:12, 1842-1853. DOI: 10.1158/2159-8290.CD-20-0047.
Thompson JC, Carpenter EL, Silva BA, et al. Serial Monitoring of Circulating Tumor DNA by Next-Generation Gene Sequencing as a Biomarker of Response and Survival in Patients With Advanced NSCLC Receiving Pembrolizumab-Based Therapy. JCO Precis; 2021: 5, 510-524. DOI: 10.1200/PO.20.0032.
In the event the test is not fully covered by insurance, patients may be eligible for financial assistance based on medical and financial need. To learn more, contact Guardant Health client services. For patients without insurance, the cash pay rate for Guardant360 TissueNext is $5,000 effective the first day of commercial launch June 22, 2021.
In the event the test is not fully covered by insurance, patients may be eligible for financial assistance based on medical and financial need. To learn more, contact Guardant Health client services. For patients without insurance, the cash pay rate for Guardant Reveal is $3,500 effective the first day of commercial launch February 26, 2021.
In the event the test is not fully covered by insurance, patients may be eligible for financial assistance based on medical and financial need. To learn more, contact Guardant Health client services. For patients without insurance, the cash pay rate for Guardant360 Response is $5,000 effective the first day of commercial launch June 22, 2021.
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept all”, you consent to the use of ALL the cookies.
Furthermore, by clicking "Accept all", you are directing us to disclose your personal information to third parties for purposes of cross-contextual behavioral advertising. For more information, please refer to our privacy policy.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
Cookie
Duration
Description
cookielawinfo-checkbox-analytics
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional
11 months
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy
11 months
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.